ACR President Carol Langford, MD, MHS, is making headlines as a leading voice in the fight against proposed Medicare reimbursement cuts that threaten the sustainability of rheumatology practices and patient access to care.
The Federal Trade Commission is seeking input about the use and impacts of noncompete agreements, with particular interest in the healthcare sector. ACR/ARP members are encouraged to share your experiences about how such agreements have affected your career and patients.
All vaccines recommended by the CDC’s ACIP)as of Sept. 1, 2025 — including updated COVID-19 and influenza shots — will be covered by health plans with no cost‐sharing for patients through the end of 2026.
The FDA will consider a supplemental new drug application for deucravacitinib for the treatment of adults with active psoriatic arthritis based on promising results from clinical trials.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.